SAREPTA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
SAREPTA THERAPEUTICS, INC. (SRPT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $4.90 million for the 12-month period ending 2013-12-31, per its 10-K filed 2014-03-03.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2014-03-03
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2013-12-31 was $1.90M, a 280.00% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2013-09-30 was $2.40M, a 380.00% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2012-12-31 was $500.00K.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2012-09-30 was $500.00K.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2013 was $4.90M, a 32.43% increase from fiscal 2012.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2012 was $3.70M, a 32.14% increase from fiscal 2011.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2011 was $2.80M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2013-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $4.30M derived: sum of 2 quarters · filed 2014-03-03 | $4.90M 10-K · filed 2014-03-03 | |
| 2013-09-30 | $2.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $3.00M 10-Q · filed 2013-11-12 | ||
| 2013-06-30 | $600.00K 10-Q · filed 2013-08-08 | |||
| 2012-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $1.00M derived: sum of 2 quarters · filed 2014-03-03 | $3.70M 10-K · filed 2014-03-03 | |
| 2012-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $3.20M 10-Q · filed 2013-11-12 | ||
| 2012-06-30 | $2.70M 10-Q · filed 2013-08-08 | |||
| 2011-12-31 | $2.80M 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |